TEVA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

31.430

Open

31.380

VWAP

30.76

Vol

10.40M

Mkt Cap

36.71B

Low

30.365

Amount

319.73M

EV/EBITDA(TTM)

9.56

Total Shares

1.16B

EV

49.89B

EV/OCF(TTM)

30.26

P/S(TTM)

2.12

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Show More

Events Timeline

(ET)

2026-03-03

17:10:00

Teva and Blackstone Life Sciences Announce $400M Strategic Funding Agreement

2026-02-20 (ET)

2026-02-20

15:00:00

Teva's TEV-'749 New Drug Application Accepted by FDA

2026-02-19 (ET)

2026-02-19

16:20:00

Walmart Announces $30 Billion Share Buyback Plan

2026-02-19

16:10:00

Corcept Disappointed by Court Ruling on Teva's Generic Drug

2026-02-19

12:10:00

Major U.S. Indices Decline as Walmart Announces $30B Buyback Plan

2026-02-19

10:40:00

Corcept Therapeutics Shares Fall 18% to $32.63

News

NASDAQ.COM

15:03 PMNASDAQ.COM

ProShares Short MSCI EAFE ETF Sees 36.6% Inflow Surge

Fool

Long-Term Investment Opportunities Amid Market Volatility

Fool

Comparing Turnarounds: Pfizer vs. Teva

Fool

Druckenmiller Cuts Pharma and Semiconductor Holdings

NASDAQ.COM

03-04NASDAQ.COM

Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks

NASDAQ.COM

03-04NASDAQ.COM

Teva and Blackstone Reach $400 Million Strategic Funding Agreement

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Piper Sandler

David Amsellem

Overweight

maintain

$40 -> $41

AI Analysis

2026-03-04

Reason

Piper Sandler

David Amsellem

Price Target

$40 -> $41

AI Analysis

2026-03-04

maintain

Overweight

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Teva to $41 from $40 and keeps an Overweight rating on the shares after meeting with management. Key discussion topics included a number of bigger picture considerations, including management's approach to innovative R&D and its vision for the R&D organization; how the team is thinking about further build-out of its core neuroscience and immunology verticals; its vision for the biosimilars business; and the approach to capital deployment amid growth in cash generation. With an attractive long-term top-line/EBITDA growth story coming into focus, in the context of continued improvement in the capital structure and an absence of loss of exclusivity exposure, the firm would argue for further multiple expansion from a current EV/2026 EBITDA of 10 times.

BofA

Buy

maintain

$37 -> $38

2026-02-18

Reason

BofA

Price Target

$37 -> $38

2026-02-18

maintain

Buy

Reason

BofA raised the firm's price target on Teva (TEVA) to $38 from $37 and keeps a Buy rating on the shares after the company and partner Sanofi (SNY) announced Phase 2 maintenance data from the RELIEVE UCCD long-term extension study of duvakitug in inflammatory bowel diseases. Based on yesterday's update, the firm edged up its multiple, reflecting $1B in higher duvakitug peak sales, now seen at a $3B peak.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 11.97, compared to its 5-year average forward P/E of 4.81. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

4.81

Current PE

11.97

Overvalued PE

6.78

Undervalued PE

2.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

6.94

Current EV/EBITDA

10.09

Overvalued EV/EBITDA

7.60

Undervalued EV/EBITDA

6.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

0.88

Current PS

2.10

Overvalued PS

1.21

Undervalued PS

0.56

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

What stoke should I buy ?

Intellectia · 60 candidates

Market Cap: >= 30.00BQuarter Revenue Yoy Growth: >= 10.0%Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Lumentum Holdings Inc

42.87B

Western Digital Corp

96.32B

Micron Technology Inc

449.96B

Comfort Systems USA Inc

47.19B

Anglogold Ashanti PLC

53.60B

Kinross Gold Corp

40.90B

stocks to buy tomorrow

Intellectia · 358 candidates

Market Cap: >= 5.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Teradyne Inc

43.25B

HF Sinclair Corp

10.32B

ArcelorMittal SA

44.06B

Archrock Inc

5.35B

Exact Sciences Corp

19.49B

American Electric Power Company Inc

64.75B

show me large cap stocks with key reversal

Intellectia · 44 candidates

Market Cap: >= 10.00BNew High Low: 52w_High, 52w_Low, 20_High, 20_LowCandlestick Pattern: UpperShadow, LowerShadow

Ticker

Name

Market Cap$

Walmart Inc

949.57B

Cisco Systems Inc

309.45B

AstraZeneca PLC

287.64B

Merck & Co Inc

273.69B

Texas Instruments Inc

193.96B

Mizuho Financial Group Inc

106.59B

stocks currently in bullish trend

Intellectia · 39 candidates

Market Cap: >= 10.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: >= $50.00Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Micron Technology Inc

439.39B

Newmont Corporation

140.53B

Carvana Co

104.69B

Freeport-McMoRan Inc

89.29B

Barrick Mining Corp

86.76B

Western Digital Corp

86.45B

give me your top pick

Intellectia · 10 candidates

Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Predict Return: >= 15.0%

Ticker

Name

Market Cap$

Ross Stores Inc

60.49B

NiSource Inc

20.77B

APi Group Corp

18.28B

Meta Platforms Inc

1.63T

EMCOR Group Inc

31.47B

Penumbra Inc

14.07B

Whales Holding TEVA

More Investment House Ltd.

Clal Financial Management Ltd

Meitav Investment House Ltd

Harel Insurance Investments & Financial Services Ltd

Rubric Capital Management LP

Altshuler Shaham Ltd.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 30.47 USD — it has decreased -3.33

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 4.72B USD, increased 12.61

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.41 USD, decreased -315.79

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

Teva Pharmaceutical Industries Ltd (TEVA) has 31173 emplpoyees as of March 11 2026.

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?

Today TEVA has the market capitalization of 36.71B USD.